Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines.
Details
- Development of Streptococcus Pneumoniae Vaccines Using Live Vectors
- Wang, Shifeng (Author)
- Curtiss, Roy (Author)
- ASU Biodesign Center Immunotherapy, Vaccines and Virotherapy (Contributor)
- Biodesign Institute (Contributor)
-
Digital object identifier: 10.3390/vaccines2010049
-
Identifier TypeInternational standard serial numberIdentifier Value2076-393X
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Wang, S., & Iii, R. C. (2014). Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines, 2(1), 49-88. doi:10.3390/vaccines2010049